Table 1.
Response of HCT116 Parental and HCT116 PTEN-/- cells to targeted inhibitors under different conditions of growth.
| Trametinib (IC50 nM) | Gedatolisib (IC50 nM) | Combo (CI) | Trametinib (IC50 nM) | Gedatolisib (IC50 nM) | Combo (CI) | |
|---|---|---|---|---|---|---|
| wo FBS | CM HFF | |||||
| HCT116 Parental | 0.02 | 4.2x103 | 50 | 0.02 | 2.2x103 | 0.01 |
| HCT116 PTEN-/- | 14x103 | >1x106 | 0.006 | 10x103 | >1x106 | 0.003 |
| Trametinib (IC50 nM) | Gedatolisib (IC50 nM) | Combo (CI) | Trametinib (IC50 nM) | Gedatolisib (IC50 nM) | Combo (CI) | |
| wo FBS | co-co with HFF | |||||
| HCT116 Parental | 0.68 | 0.4x103 | 1.2 | 1.03 | 0.08x103 | 0.0007 |
| HCT116 PTEN-/- | 24.4 | 0.37x103 | 0.07 | 6.35 | 0.32x103 | 0.99 |
IC50 and CI for all the drugs in absence of FBS (i.e. wo FBS) are intrinsically differ each other comparing to HFF-CM and co-co with HFF due to the different experimental setting conditions.